Chrysalis launches with acquired cleanroom assets to deliver flexible manufacturing solutions

With facilities in Massachusetts and North Carolina, Chrysalis offers flexible, GMP-compliant cleanroom spaces and support that help life science innovators and biopharma companies accelerate the development of transformative therapies. At a time where there is increasing pressures to progress quickly through key milestones to clinic and beyond, Chrysalis enables innovators to retain full ownership of their programs to meet their unique timelines and technical requirements. 

“Our model is particularly valuable for programs where retaining process control, protecting IP, and minimizing risk are crucial considerations,” said Sarah Stevens, CEO of Chrysalis. 

“Our approach gives our customers flexibility to take only the space and services they need, when they need it. By providing rapid access to GMP-compliant space and operational support, we empower our customers to advance on their own terms, transforming scientific promise into real progress without the burden of scheduling constraints or unnecessary ongoing expense.” 

With entry to cleanroom times as short as four to six weeks, Chrysalis offers tailored, cleanroom environments on flexible terms. This allows clients to flex manufacturing activities in line with their project needs and milestones, minimizing expenditure while maximizing control.

Chrysalis partners with a wide spectrum of life science clients, from early-stage biotech companies to top 10 pharmaceutical firms, contract research organizations (CROs), and other life science stakeholders by providing fit-for-purpose space in key U.S. innovation hubs. Its facilities accommodate a wide array of therapeutic modalities and technical needs, helping clients maintain control and adapt quickly as their programs evolve.

Sarah added: “Whether clients are navigating early development or preparing for commercialization, we’re here to grow with them. We don’t just provide space, we build partnerships grounded in collaborative operational excellence and a deep understanding of what it takes to operate in a GMP environment.” 

Chrysalis is positioned to scale rapidly, enhance its infrastructure, expand into additional geographies, and extend its service offerings to meet the growing demand for agile manufacturing solutions.